Abatacept

Phase 1Completed

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Female Patients With Behcet's Syndrome

Conditions

Female Patients With Behcet's Syndrome

Trial Timeline

Jun 1, 2012 → Dec 28, 2018

NCT ID

NCT01693640

About Abatacept

Abatacept is a phase 1 stage product being developed by Bristol Myers Squibb for Female Patients With Behcet's Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT01693640. Target conditions include Female Patients With Behcet's Syndrome.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05170672	Pre-clinical	Completed	—	—	—
NCT05981976	Phase 1	Completed	Aug 18, 2023	Dec 14, 2023	Healthy Participants
NCT04925375	Phase 2	Recruiting	Jul 14, 2021	Jul 1, 2026	Interstitial Lung Disease
NCT04472494	Phase 2	Terminated	Oct 14, 2020	Sep 13, 2021	COVID-19
NCT04477642	Phase 1/2	Withdrawn	Aug 1, 2020	Dec 1, 2020	COVID-19
NCT03924401	Phase 2	Active	Aug 22, 2019	Mar 1, 2027	Graft Versus Host Disease
NCT03882008	Approved	Completed	May 23, 2019	Jun 30, 2023	Rheumatoid Arthritis
NCT03669861	Phase 2	Completed	Nov 13, 2018	Nov 10, 2020	IgG4-related Disease
NCT03714022	Phase 1	Completed	Nov 9, 2018	Apr 2, 2019	Rheumatoid Arthritis
NCT03084419	Phase 2	UNKNOWN	Jun 26, 2018	Mar 1, 2020	Rheumatoid Arthritis
NCT03215927	Phase 2	Completed	Jan 1, 2018	Jul 30, 2023	Myositis
NCT02915159	Phase 3	Completed	Dec 6, 2016	Jul 23, 2019	Sjogrens Disease
NCT02805010	Phase 1	UNKNOWN	Oct 1, 2016	Feb 1, 2017	Rheumatoid Arthritis (RA)
NCT02037737	Pre-clinical	Completed	Sep 30, 2016	Jan 31, 2018	Rheumatoid Arthritis
NCT02592798	Phase 2	Completed	Mar 9, 2016	Jan 28, 2020	Nephrotic Syndrome
NCT02598466	Pre-clinical	Completed	Jul 1, 2015	Jan 1, 2016	Rheumatoid Arthritis
NCT02281058	Phase 1	UNKNOWN	Jan 1, 2015	May 1, 2018	Vitiligo
NCT02078882	Approved	Completed	Sep 1, 2014	Oct 1, 2018	Primary Biliary Cirrhosis
NCT01954979	Phase 1	Completed	Mar 27, 2014	Jan 16, 2024	Chronic Graft Versus Host Disease
NCT02169544	Pre-clinical	Completed	Jan 31, 2014	Feb 28, 2017	Rheumatoid Arthritis

Competing Products

20 competing products in Female Patients With Behcet's Syndrome

See all competitors

Product	Company	Stage	Hype Score
Fulvestrant + Abemaciclib	Eli Lilly	Phase 2	52
Gemcitabine + liposomal doxorubicin	Eli Lilly	Phase 3	77
ASP3325 + Placebo	Astellas Pharma	Phase 1	33
Ensitrelvir	Shionogi	Phase 1	33
Eribulin Injection [Halaven] + Paclitaxel injection	Eisai	Approved	85
Gemcitabine + Paclitaxel + Carboplatin	Eli Lilly	Phase 3	77
Abemaciclib 50 MG; 150mg 1-0-1 per os	Eli Lilly	Phase 3	77
Abemaciclib, durvalumab and aromatase inhibitor	Eli Lilly	Phase 1	33
norelgestromin/ethinyl estradiol (NGMN/EE) transdermal contraceptive system.	Johnson & Johnson	Phase 1	33
Norgestimate/Ehinyl Estradiol; Folic acid.	Johnson & Johnson	Phase 1	33
SHR6390 + placebo	Jiangsu Hengrui Medicine	Phase 3	77
SHR7280 tablets	Jiangsu Hengrui Medicine	Phase 2	52
SHR7280；Ganirelix Acetate Injection simulant + SHR7280 simulant； Ganirelix Acetate Injection	Jiangsu Hengrui Medicine	Phase 3	77
SHR3162	Jiangsu Hengrui Medicine	Phase 1	33
AZD3293 + Placebo	AstraZeneca	Phase 1	33
Fulvestrant 500mg + Palbociclib 125mg + Goserelin 3.6 MG + Placebos	AstraZeneca	Phase 3	77
AZD2516 + Placebo	AstraZeneca	Phase 1	33
Durvalumab + Tremelimumab	AstraZeneca	Phase 2	52
Dapagliflozin + Metformin + Dapagliflozin + Metformin	AstraZeneca	Phase 1	33
AZD4901 (oral) + Placebo to match AZD4901	AstraZeneca	Phase 2	52

Other Products from Bristol Myers Squibb

DeucravacitinibApproved

Aripiprazole + Olanzapine + HaloperidolApproved

Irbesartan + CiprofibrateApproved

Entecavir + Lamivudine Placebo + Lamivudine + Entecavir PlaceboApproved

deucravacitinibApproved